obesity research raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-05-27. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
== Signs and symptoms == Clinical features may include constitutional symptoms like fever, arthralgia, myalgia, loss of appetite, weight loss and fatigue. A variety of organs can be affected, which causes a wide range of symptoms such as cough, shortness of breath, hemoptysis (coughing up of blood), symptoms of kidney failure, skin manifestations (palpable purpura and livedo racemosa), seizures or peripheral neuropathy, abdominal pain. The kidneys are affected in up to 80% of cases with signs of blood and protein in the urine and the injury can lead to either rapidly or slowly progressive kidney failure. The lungs are affected in 20-50% of cases with findings of pulmonary hemorrhage, or chronic pulmonary fibrosis leading to respiratory failure.
== Applications == TCEP is often used as a reducing agent to break disulfide bonds within and between proteins as a preparatory step for gel electrophoresis. Compared to the other two most common agents used for this purpose (dithiothreitol and β-mercaptoethanol), TCEP has the advantages of being odorless, a more powerful reducing agent, an irreversible reducing agent (in the sense that TCEP does not regenerate—the end product of TCEP-mediated disulfide cleavage is in fact two free thiols/cysteines), more hydrophilic, and more resistant to oxidation in air. It also does not reduce metals used in immobilized metal affinity chromatography. TCEP is particularly useful when labeling cysteine residues with maleimides. TCEP can keep the cysteines from forming di-sulfide bonds and, unlike dithiothreitol and β-mercaptoethanol, it will not react as readily with the maleimide. However, TCEP has been reported to react with maleimide under certain conditions. TCEP is also used in the tissue homogenization process for RNA isolation. For Ultraviolet–visible spectroscopy applications, TCEP is useful when it is important to avoid interfering absorbance from 250 to 285 nanometers which can occur with dithiothreitol. Dithiothreitol will slowly over time absorb more and more light in this spectrum as various redox reactions occur.
=== Inherent instability of the enediyne core === The instability toward Bergman cyclization–reduction decomposition pathways poses a major threat to any proposed synthesis of enediynes. Myers and co-workers addressed this liability by late-stage dehydrative installation of the olefin. Without this unsaturation linking the two alkynyl bridges, synthetic intermediates are not disposed toward Bergman-type decomposition, and risk of decomposition is mitigated. In this case, dehydration of a propargylic alcohol was induced by treatment with Martin sulfurane.
=== Music === Season 3 is the only Euphoria season not scored by British composer Labrinth. On July 23, 2025, he announced he was working with German composer Hans Zimmer for the season. But on March 13, 2026, Labrinth posted an Instagram story that read, "Fuck Columbia. Double Fuck Euphoria. I'm out. Thank you and good night." Labrinth removed all his music from the show, leaving Zimmer as the sole music composer.
Although HVEC ceased accelerator production in 1981, many of its machines remain active in nuclear physics research. Several have operated continuously for more than 50 years. Beyond AMS, active accelerators are used for nuclear astrophysics (studying neutron-induced reactions relevant to stellar nucleosynthesis), ion beam analysis, radiation effects testing, and ion-atom collision physics. Four remain at U.S. national laboratories: Argonne, Brookhaven, Lawrence Livermore, and Sandia. High Voltage Engineering Europa, the former Dutch subsidiary, continues manufacturing electrostatic accelerators for research and industrial applications.
Sources: en.wikipedia.org
=== Pregnancy and breastfeeding === The safety of using omeprazole has not been established in pregnant or breastfeeding women. Epidemiological data do not show an increased risk of major birth defects after maternal use of omeprazole during pregnancy.
=== November === 1 November – Non-teaching staff belonging to the UNISON union at schools in Dundee City, Stirling, Clackmannanshire, Angus and Perth and Kinross announce strikes in the areas on 15 November. 2 November – The City of Edinburgh Council declares a housing emergency, citing the high number of homeless people in the city coupled with a shortage of social housing and high private renting costs. 3 November – First Minister Humza Yousaf confirms his in-laws have crossed the border from Gaza into Egypt. The Unison trade union suspends further school strikes in Scotland after receiving a revised pay offer from the Scottish Government, which will be put to its members in a ballot. Fiona, a sheep believed to have been stranded on the banks of the Moray Firth for two years, is rescued. 4 November – Pro-Palestinian protestors occupy two of Scotland's major railway stations, Edinburgh Waverley and Glasgow Central, during another day of protests as the war in Gaza continues. 5 November – Eight police officers are injured following Bonfire Night clashes with youths during which fireworks and petrol bombs are thrown; the most serious incident takes place in the Niddrie area of Edinburgh, where 50 youths clash with police. Two people are subsequently arrested over the Niddrie incident. Humza Yousaf's parents in-laws return to Scotland.
Polyethersulfone (PES) is also referred to as polyetherketone and polysulfone. It is synthesized by nucleophilic aromatic substitution between aromatic dihalides and bisphenolate salts. Polyethersulfones are partially crystalline and highly resistant to a wide range of aqueous and organic environments. They are rated for continuous service at temperatures of 240–280 °C. The polyketones are finding applications in areas like automotive, aerospace, electrical-electronic cable insulation.
His crimes, which targeted around 3,500 children across 30 countries, are described by Mr Justice O'Hara as ones of "sadism and depravity" which "scarred" the childhoods of his victims. Appearing at the Old Bailey, Dylan Earl pleads guilty to carrying out an arson attack on a Ukrainian-owned business in east London on behalf of Russia. A Scottish couple are given permission to proceed with a legal case that will attempt to overturn the scrapping of universal winter fuel payments for pensioners. 27 October – Labour MP Mike Amesbury is suspended from the party and has the whip withdrawn, after CCTV footage emerges appearing to show him punching a man to the ground. 28 October Far-right activist Tommy Robinson is sentenced to 18 months in prison for contempt of court for repeating false allegations against a Syrian refugee, in breach of an injunction. Manchester United sack manager Erik ten Hag less than 24 hours after a 2–1 defeat to West Ham United, leaving the club in 14th place after nine games. Assistant Ruud van Nistelrooy takes charge on an interim basis until a permanent replacement is found. 30 October October 2024 United Kingdom budget: Rachel Reeves unveils her first budget as chancellor, which includes £40bn in tax rises, intended to offset what she alleges is a £22bn "black hole" in the nation's finances, while enabling the largest hike in NHS funding since 2010. The first case of Clade Ib mpox, a more spreadable variant linked to the outbreak in Africa, is detected in the UK.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.